Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.

@article{Anand2011IncreasedBI,
  title={Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.},
  author={Shubha Anand and F. Stedham and Emma J Gudgin and Peter J. Campbell and Phillip Beer and Anthony R. Green and Brian J. P. Huntly},
  journal={Blood},
  year={2011},
  volume={118 6},
  pages={
          1610-21
        }
}
Myeloproliferative neoplasms (MPNs) are associated with recurrent activating mutations of signaling proteins such as Janus kinase 2 (JAK2). However, the actual downstream signaling events and how these alter myeloid homeostasis are poorly understood. We developed an assay to measure basal levels of phosphorylated signaling intermediates by flow cytometry during myeloid differentiation in MPN patients. Our study provides the first systematic demonstration of specific signaling events and their… 

Figures and Tables from this paper

JAK2 inhibitors in the treatment of myeloproliferative neoplasms
TLDR
Understanding the intricacies of JAK-STAT pathway activation, including growth factor/cytokine-driven signaling, will open new avenues for therapeutic intervention at known and novel molecular vulnerabilities of MPNs.
AKT is a therapeutic target in myeloproliferative neoplasms
TLDR
Findings establish AKT as a rational therapeutic target in the MPNs by showing that inhibition of PI3K/AKT signaling by MK-2206 affected the growth of both JAK2V617F- or MPLW515L-expressing cells via reduced phosphorylation of AKT and inhibition of its downstream signaling molecules.
Disordered signaling in myeloproliferative neoplasms.
Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs)
TLDR
Early murine model development of JAK2V617F is described, with an analysis of its effects on the hematopoietic stem/progenitor cell niche and interactions with downstream signaling elements and a description of more recent in vivo models developed for evaluating the effect of concomitant mutations in epigenetic modifiers on MPN maintenance and progression.
pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms
TLDR
The demonstration of distinct STAT staining patterns in molecularly defined MPN suggests that these mutations result in divergent signaling events that may contribute to the biological and prognostic differences in these molecular subsets of MPN.
The JAK2 mutation.
  • S. Merchant
  • Biology
    International review of cell and molecular biology
  • 2021
Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity
TLDR
Increased constitutive p-STAT5 and IL6 induced p- STAT3 values in circulating CD34+ cells characterize patients with PMF, pointing toward a complex activation of STAT5-dependent pathways in the stem/progenitor cell compartment, that characterize the phenotypic diversity of PMF.
A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation
TLDR
Data link aberrant MAPK activation to the MPN phenotype and identify it as a potential therapeutic target in CALR-mutant positive MPNs, a novel strategy that utilizes the full range of kinase selectivity data available from each inhibitor and takes advantage of off-target noise that limits conventional small-interfering RNA or inhibitor screens.
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
TLDR
The Janus kinase 2 (JAK2) mutant V617F and other JAK mutants are found in patients with myeloproliferative neoplasms and leukemias and their inhibition by small-molecule kinase inhibitors are discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Aberrant signal transduction pathways in myeloproliferative neoplasms
TLDR
Recent progress made in deciphering signaling anomalies in PV, ET and PMF is reviewed, with an emphasis on the relationship between JAK2 V617F and cytokine receptor signaling and on cross-talk with several other signaling pathways.
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
TLDR
Activation of JAK-STAT signaling via MPLW515L is an important pathogenetic event in patients with JAK2V617F-negative MF, including extramedullary hematopoiesis, splenomegaly, and megakaryocytic proliferation.
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia
TLDR
The results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis.
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
TLDR
A clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (> 80%) polycythaemia vera patients leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
TLDR
Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis, consistent with the hypothesis that the ratio of mutant to wild-type JAK1 is critical for the phenotypic manifestation.
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
TLDR
Hematopoietic progenitor assays demonstrated that the differentiation potential of PV was already skewed toward the erythroid lineage at the HSC level, and the aberrant erytroid Potential of PV HSC was potently inhibited with a JAK2 inhibitor, AG490.
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
JAK2 and MPL mutations are recurrent in myeloproliferative neoplasms (MPNs). A JAK2 mutation, primarily JAK2V617F, is almost invariably associated with polycythemia vera (PV). However, JAK2V617F also
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
TLDR
Four somatic gain-of-function mutations affecting JAK2 exon 12 define a distinctive myeloproliferative syndrome that affects patients who currently receive a diagnosis of polycythemia vera or idiopathic erythrocytosis.
...
1
2
3
4
...